Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers find potential new genetic chemotherapy approach for cancer treatment

Researchers find potential new genetic chemotherapy approach for cancer treatment

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

New partnership to introduce advanced genetic testing technologies to Turkey

New partnership to introduce advanced genetic testing technologies to Turkey

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Michigan's first cardio-oncology clinic launched to prevent heart problems

Michigan's first cardio-oncology clinic launched to prevent heart problems

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

MD Anderson scientists demonstrate new way to restore tumor suppression

MD Anderson scientists demonstrate new way to restore tumor suppression

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

New immunotherapies are seldom developed for childhood cancer

New immunotherapies are seldom developed for childhood cancer

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

MD Anderson professor to receive award for clinical research excellence at AACR meeting

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

American Society of Hematology announces first recipients of ASH Bridge Grants

American Society of Hematology announces first recipients of ASH Bridge Grants

American Cancer Society announces new research, training grants for fiscal year 2013

American Cancer Society announces new research, training grants for fiscal year 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

GE Healthcare releases next-generation sequencing assay for use in clinical trials

GE Healthcare releases next-generation sequencing assay for use in clinical trials

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.